PEAK6
NTLA icon

PEAK6’s Intellia Therapeutics NTLA Stock Holding History

PEAK6’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-374
Closed -$3.36K – 3109
2025
Q4 		$3.36K Buy
+374
New +$5.15K ﹤0.01% 2688
2025
Q3 		– Sell
-7,601
Closed -$93.6K – 3310
2025
Q2 		$71.3K Buy
7,601
+6,543
+618% +$53.7K ﹤0.01% 2664
2025
Q1 		$7.52K Sell
1,058
-29,653
-97% -$300K ﹤0.01% 2797
2024
Q4 		$358K Buy
+30,711
New +$479K ﹤0.01% 2311

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

PEAK6's NTLA Position: Q1 2026 in Review

PEAK6 sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 374 shares — an estimated $3.36K sold.

PEAK6 first reported a position in NTLA in Q4 2024 and held it in 4 quarters. The position peaked at $358K in Q4 2024. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • PEAK6 reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • PEAK6 sold 374 Intellia Therapeutics shares in Q1 2026, an estimated $3.36K.
  • PEAK6 first reported a position in Intellia Therapeutics in Q4 2024 and held it in 4 quarters.
  • PEAK6's Intellia Therapeutics position peaked at $358K in Q4 2024.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on PEAK6's 13F filing for Q1 2026, filed 14 May 2026.